TG Therapeutics has recently been granted three new patents by the United States Patent and Trademark Office (USPTO) for their drug BRIUMVI, which is utilized in the treatment of relapsing forms of multiple sclerosis. The issuance of these patents ensures that the exclusive rights to ublituximab, the key component in BRIUMVI, will be upheld until 2042.
These patents specifically focus on the composition of ublituximab, offering extended protection for the drug. This milestone paves the way for TG Therapeutics to further explore the capabilities of BRIUMVI, potentially broadening its applications in the realm of multiple sclerosis and other autoimmune conditions.
This announcement marks a significant advancement for TG Therapeutics and underscores their commitment to advancing treatment options for patients battling multiple sclerosis.
TG Therapeutics Inc. (TGTX) Shows Positive Price Momentum Despite Trading Near Bottom: February 27, 2024 Analysis
On February 27, 2024, TG Therapeutics Inc. (TGTX) was trading near the bottom of its 52-week range and below its 200-day simple moving average, according to data from CNN Money. Despite this, the stock showed some positive price momentum on that day.
TGTX shares saw a slight increase of $0.04 since the market last closed, representing a 0.30% rise. In pre-market trading, TGTX saw a further increase of $0.79, indicating some bullish sentiment among investors.
While trading near the bottom of its 52-week range and below its 200-day moving average may raise concerns for some investors, the positive price momentum on February 27th could be a sign of potential upside for TGTX. Investors interested in TG Therapeutics Inc. should continue to monitor the stock’s performance and consider conducting further research to make informed investment decisions.
TG Therapeutics (TGTX) Stock Performance Analysis: Mixed Results on February 27, 2024
On February 27, 2024, TG Therapeutics (TGTX) stock experienced mixed performances based on the company’s financial data. According to CNN Money, TGTX reported a total revenue of $2.79 million for the past year, which represented a significant decrease of 58.36% compared to the previous year. However, in the latest quarter, the company reported a total revenue of $165.81 million, showing a remarkable increase of 931.57% since the previous quarter. In terms of net income, TGTX reported a net loss of $198.34 million for the past year, which was an improvement of 43.02% compared to the previous year. In the latest quarter, the company reported a net income of $113.93 million, representing a substantial increase of 339.3% since the previous quarter. Earnings per share (EPS) also showed positive trends for TGTX. The company reported an EPS of -$1.46 for the past year, which was an increase of 44.37% compared to the previous year. In the latest quarter, TGTX reported an EPS of $0.73, showing a significant increase of 317.21% since the previous quarter. Overall, the financial data for TG Therapeutics on February 27, 2024, indicated both positive and negative performances. While the company experienced a decrease in total revenue compared to the previous year, the significant increase in revenue and net income in the latest quarter demonstrated promising growth potential for TGTX. Investors and analysts may want to closely monitor the company’s future financial reports to assess its continued performance in the market.
